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Background: The question of whether the choice of preservation solution affects outcome after liver
transplantation is still not satisfactorily answered. The purpose of this study is to examine the preservation solutions’
impact on outcome after liver transplantation.
Methods: A double-center retrospective study of short- and long-term results of 3134 consecutive liver transplantations
with follow-up periods up to 23 years was performed applying multivariate, risk-adjusted analyses with a subset for
living-donor transplants, pediatric transplants and cases with prolonged cold ischemic times. An additional focus was
put on biliary complications. The primary study endpoints were short- and long-term patient survival and death-censored
graft survival. Secondary study endpoints were the occurrence of post-transplant complications, the necessity of operative
revisions, the length of hospital stay, and the length of intensive care unit stay.
Results: Although long-term graft survival appears to be increased by Histidine-Tryptophan-Ketoglutarate-use (p = 0.018),
this effect could not be confirmed in risk-adjusted analysis (p = 0.641). Multivariate regression analysis revealed that
3-month mortality (p = 0.120), 3-month graft survival (p = 0.103) and long-term patient survival (p = 0.235) were not
influenced by the choice of preservation solution. There was no difference in the occurrence of common complications
or necessity of operative revisions after liver transplantation. This was confirmed in subgroup analyses for living donor and
pediatric transplantation and cases with prolonged cold ischemic time. Analysis of the preservation solutions’ impact on
length of hospital (p = 0.113) and intensive care unit stay (p = 0.481) revealed no significant difference.
Conclusions: University of Wisconsin and Histidine-Tryptophan-Ketoglutarate solutions are clinically equivalent.
Histidine-Tryptophan-Ketoglutarate solution could have an economically superior profile. The notion that the choice
of preservation solution can have an impact on the onset of biliary complications after liver transplantation remains a
matter of controversy.
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University of Wisconsin (UW) and Histidine-Tryptophan-
Ketoglutarate (HTK) solutions are both used for organ
preservation in liver transplantation (LTX). Both have been
applied for decades largely depending on local preferences
with several known differences. UW is characterized by
low osmolarity, the containment of colloid and several
radical scavengers, such as adenosine and glutathione
[1]. It revolutionized organ preservation in 1987 by
facilitating “semi-elective” LTX [2]. HTK was developed by
Bretschneider and colleagues in 1975, originally for cardio-
plegia [1]. In 2002, the US Food and Drug Administration
approved HTK for preservation of donor livers. It is
characterized by a lower osmolarity than UW, a strong
histidine buffer system which increases the osmotic effect
of mannitol and lower electrolyte concentrations [1,3].
The effects of the choice of preservation solution (PS)
on outcome after organ transplantation are still a matter
of controversy. A systematic review of reports published
until 2007 with a total of 1200 liver transplant recipients
states that both are equally effective [4]. More recent
data from the UNOS database points to preferable
characteristics of UW, especially in means of graft
survival [5]. Furthermore, the impact of PS on the
onset of biliary complications still remains unclear,
since there are reports suggesting equivalent [6,7] as
well as differing risk profiles [8-10]. However, most of
the available literature is limited by its single-center
study character, small sample sizes and only short- to
medium-term follow-up schemes.
We performed a double-center, data-base driven
statistical analysis of the short- and long-term results
of more than 3100 liver transplant recipients. Narrowly
scoped subset-analyses were performed additionally for
living-donor transplants, pediatric transplants, as well
as cases with prolonged cold ischemic time (CIT).
Additionally, a focused investigation of biliary complications
was part of this analysis.
Methods
This is a double-center, retrospective, observational study
from two German liver transplant centers within the
Eurotransplant community. The study was designed
according to the Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE)-Guidelines
(see STROBE-checklist as Additional file 1). Hannover
Medical School provided data of 2554 consecutive
liver transplants (1377 males [53.9%]; 1177 females
[46.1%]) with a median recipient age of 43 years at
transplant (range 0-74 years) performed between the
01.06.1987 and the 31.12.2012. Mean follow-up in this
cohort is 5.7 years (median 3.9 years; range 0-22 years).
The University Hospital Kiel provided data of 580
consecutive transplants (336 males [57.9%]; 244 females[42.1%]) with a median recipient age of 52 years at
transplant (range 0-75 years) performed between the
01.11.1988 and the 09.02.2013. Mean follow-up in this
cohort is 3.1 years (median 3.2; range 0-23.3 years).
Only patients with either HTK or UW usage were included.
Cases with missing data over more than 10% of follow-up
time were excluded from analyses. The primary study
endpoints were short- and long-term patient survival as
well as death-censored graft survival. Short-term patient
and graft survival was defined as 90 days post-transplant.
The secondary study endpoints were the occurrence of
post-transplant complications (hepatic artery thrombosis
(HAT), portal vein thrombosis (PVT), caval vein throm-
bosis, post-operative hemorrhage, biliary complications),
the necessity of operative revisions, the length of hospital
stay, and the length of intensive care unit (ICU) stay.
Ethical considerations
As an observational retrospective study, according to the
Professional Code of the German Medical Association
(article B.III. § 15.1), neither informed consent nor approval
of the ethics committee was needed for this study. This
study is in compliance with the Helsinki Declaration.
Statistical methods
This is an analysis of prospectively stored and retrospect-
ively compiled data. Age at transplant, recipient sex, alloca-
tion era (I: early phase center allocation 01/01/1987-31/12/
1992; II: late phase center allocation 01/01/1993-30/06/
2000; III: Child-Pugh-based allocation system 01/07/2000-
01/01/2007; IV: Model of End-Stage Liver Disease-based
allocation 01/01/2007-09/02/2013), living-donor transplant,
experience of the operating surgeon (defined as previously
performed LTX as leading surgeon), CIT, pediatric patient
(defined as younger than 18 years), operative duration,
combined transplant, number of post-operative revisions,
complications (as listed above), as well as the cohort’s five
most common indications leading to transplant (see Table 1)
were analyzed as possible risk factors with influence on the
primary and secondary study endpoints. Their relevance was
identified with univariate binary regression and Cox regres-
sion analysis respectively. To avoid over-fitting, all variables
with an alpha-level <0.1 were considered for risk-adjusted
multivariate regression analyses, which were performed to
examine variations in risk according to usage of either UW
or HTK solution. Kaplan-Meier analysis with Log Rank
Tests, Pearson’s Chi2-test or ANOVA-analysis were applied
where appropriate. For all statistical tests a p-value <0.05
was defined as significant. The IBM SPSS statistics-software
version 21.0 was used to perform statistical analysis.
Additional subset analysis
An additional detailed subset investigation was performed
for the Hannover cohort’s living donor related transplants
Table 1 The five most common indications for liver transplantation in the Hannover and Kiel cohort
Hannover cohort Kiel cohort
Indication Number of patients (% of cohort) Indication Number of patients (% of cohort)
1 Viral hepatitis 334 (13.0%) Alcoholic cirrhosis 119 (20.5%)
2 Hepatocellular carcinoma 281 (11.0%) Viral hepatitis 86 (14.8%)
3 Acute liver failure 246 (9.6%) Hepatocellular carcinoma 43 (7.4%)
4 Primary sclerosing cholangitis 196 (7.7%) Biliary atresia 41 (7.1%)
5 Biliary atresia 192 (7.5%) Acute liver failure 36 (6.2%)
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patients with prolonged CIT (n = 346; 13.5%). Prolonged
CIT was defined as the mean CIT (622 min) plus
the standard deviation (239 min) which results in a
CIT > 861 min (the CIT was normally distributed,
Kolmogorov-Smirnov-Test: p < 0.001).
Amount of preservation solution
The Kiel data-base stored data on the perfused amounts
of UW and HTK solution for 507 patients (87.4%).
This data was investigated as a continuous variable in
risk-adjusted regression modeling to assess its influence on
the primary and secondary study endpoints. We aimed to
reveal a potential dose-dependent effect of the preservation
solution on outcome with this analysis. Furthermore,
addition of the Kiel cohort served to confirm the results
from the Hannover analysis and aimed to reduce possible
center bias.
Clinical handling of UW and HTK
Before application, several additives, such as prostaglandin
E1 and/or dexamethason have to be added to UW solution.Table 2 Distribution of primary and secondary study endpoin
2554 patients from the Hannover liver transplant program
I II
n (%) 346 (13.5%) 773 (30.3%
HTK 32 (9.2%) 470 (60.8%
UW 314 (90.8%) 303 (39.2%
3 months mortality 82 (23.7%) 142 (18.4%
graft loss 224 (64.7%) 374 (48.4%
3 month graft survival 238 (68.8%) 582 (75.3%
HAT 14 (4.0%) 19 (2.5%)
Portal vein thrombosis 6 (1.9%) 7 (0.9%)
Caval vein thrombosis 1 (0.3%) 4 (0.5%)
Post-operative hemorrhage 73 (22.7%) 197 (25.9%
Biliary complications 34 (16.9%) 127 (16.7%
Mean LOS in days (SD) 44 (34) 40 (30)
HTK = Histidine-Tryptophane-Ketoglutarate solution; UW = University of Wisconsin s
of hospital stay.
1Pearson’s Chi2 Test.
2ANOVA.Once these components have been mixed, the solution
must be used within 24h. In contrast, HTK solution can be
used right away and no further additives are needed. From
a clinical point of view, HTK can be quicker perfused
without any need for pressurized perfusion. This is due to
HTK’s comparatively low viscosity, which equals the one
of water (2.0 cP). The viscosity of UW is higher (6.2 cP)
because of the presence of colloids [1,11].
Results
Descriptive statistics of the two cohorts and the distribution
of UW vs. HTK solution are summarized in Tables 2, 3 and
4. In Hannover, UW was used in 1091 transplants (42.7%)
and HTK in 1463 transplants (57.3%). In Kiel, livers were
perfused 223 times with UW (38.4%) and 375 times with
HTK (61.6%). The distribution and development of solution
usage above time is depicted in Figure 1.
The Hannover cohort
Patient survival
In Kaplan-Meier analysis the type of PS has no statistically
significant impact on long-term patient survival (p = 0.235)ts as well as preservation solutions to the different eras,
Era
III IV p-value
) 811 (31.8%) 624 (24.4%) n.a.
) 439 (54.1%) 522 (83.7%) <0.0011
) 372 (45.9%) 102 (16.3%) <0.0011
) 112 (13.8%) 98 (15.7%) <0.0011
) 281 (34.6%) 171 (27.4%) <0.0011
) 645 (79.5%) 482 (77.4%) 0.0011
30 (3.8%) 37 (6.0%) 0.0101
24 (3.1%) 27 (4.4%) 0.0011
10 (1.3%) 31 (5.0%) <0.0011
) 162 (20.8%) 169 (27.3%) 0.0201
) 169 (21.7%) 138 (22.3%) 0.0151
41 (35) 51 (43) <0.0012
olution; SD = Standard Deviation; HAT = hepatic artery thrombosis; LOS = length
Table 3 Distribution of primary and secondary study endpoints as well as preservation solutions to the different eras,
580 patients from the Kiel liver transplant program
Era
I II III IV p-value
n (%) 9 (1.6%) 96 (16.6%) 152 (26.2%) 323 (55.7%) n.a.
HTK 0 (0%) 8 (8.3%) 68 (44.7%) 281 (87.0%) <0.0011
UW 9 (100.0%) 88 (91.7%) 84 (55.3%) 42 (13%) <0.0011
3 months mortality 3 (33.3%) 22 (22.9%) 35 (23.0%) 32 (9.9%) <0.0011
graft loss 8 (88.9%) 59 (61.5%) 75 (49.7%) 85 (26.5%) <0.0011
3 month graft survival 6 (66.7%) 68 (70.8%) 106 (69.7%) 262 (81.1%) 0.0211
Biliary complications 1 (11.1%) 33 (34.4%) 47 (30.9%) 18 (19.4%) 0.0991
HTK = Histidine-Tryptophane-Ketoglutarate solution; UW = University of Wisconsin solution; SD = Standard Deviation.
1Pearson’s Chi2 Test.
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nificantly affected by the type of preservation solution
(p = 0.120).
Graft survival
Univariate Kaplan-Meier analysis demonstrated that
HTK is beneficial for long-term graft survival (p = 0.018;
Log-Rank) (Figure 2B). This result could not be con-
firmed in multivariate Cox regression (p = 0.641),
which was adjusted for necessity of operative revisions
(p < 0.001; HR:1.943; 95%-CI:1.711-2.206), occurrence of
HAT (p < 0.001; HR:4.306; 95%-CI:3.447-5.379), PVT
(p < 0.001; HR:1.973; 95%-CI:1.414-2.784), post-operative
hemorrhage (p < 0.001; HR:1.540; 95%-CI:1.346-1.763), bil-
iary complications (p = 0.003; HR:1.260; 95%-CI:1.086-1.461),
age at transplant (p < 0.001; HR:1.007; 95%-CI:1.004-1.011),
living-donor LTX (p < 0.001; HR:0.539; 95%-CI:0.370-0.785),
CIT (p < 0.001; HR:1.001; 95%-CI:1.000-1.001), pediatric
LTX (p = 0.001; HR:0.775; 95%-CI:0.662-0.908), era in which
the transplant was performed (p < 0.001; HR:0.811; 95%-
CI:0.760-0.866), the indication hepatocellular carcinomaTable 4 Shown are clinical characteristics of the two
investigated cohorts from Hannover Medical School and
University Hospital Kiel
Variable Hannover cohort Kiel cohort
n 2554 580




Median age (range) 43 (0-74) years 52 (0-75) years
UW (n; %) 1091 (42.7%) 223 (38.4%)
HTK (n; %) 1463 (57.3%) 375 (61.6%)
CIT (mean; range) in min. 621.6 (80-1970) 601.5 (210-1320)
Living donor (n; %) 125 (4.9%) 80 (13.8%)
Pediatric recipient (n; %) 575 (22.5%) 87 (15.0%)
HTK = Histidine-Tryptophane-Ketoglutarate solution; UW = University of
Wisconsin solution; CIT = cold ischemic time.(HCC) (yes/no) (p = 0.022; HR:1.247; 95%-CI:1.038-1.498),
the indication primary sclerosing cholangitis (PSC)
(yes/no) (p = 0.001; HR:0.651; 95%-CI:0.501-0.847) and
the indication biliary atresia (yes/no) (p = 0.007; HR:0.702;
95%-CI:0.535-0.921). Three-month graft survival was not
affected by the type of PS (p = 0.103).
Complications after LTX
The choice of PS did not influence the occurrence
of HAT (p = 0.850), nor of PVT (p = 0.761), caval
vein thrombosis (p = 0.053), post-operative hemorrhage
(p = 0.273), biliary complications (p = 0.178) and necessity
of operative revisions (p = 0.120) after LTX.
Biliary complications (n = 488; 19.1%) have been further
analyzed on a more detailed level, because of previously
reported associations of these with the PS [11-13]. They
were categorized into biliary leaks (n = 218; 44.7%),
stenosis (n = 77; 15.8%), cholangitis (n = 80; 16.4%) and not
further specified biliary complications (n = 129; 26.4%). In
univariate regression analysis, beneficial effects on biliary
leakage (p = 0.035; OR:0.735; 95%-CI: 0.531-0.982) and
biliary stenosis (p = 0.011; OR:0.532; 95%-CI: 0.323-0.879)
were associated with HTK-preservation. This result for
biliary leakage could not be verified in a multivariate binary
regression model (p = 0.572), which was adjusted for the
occurrence of HAT (p = 0.001; OR:2.566; 95%-CI:1.525-
4.317), caval thrombosis (p = 0.043; OR:2.227; 95%-CI:1.025-
4.835), post-operative hemorrhage (p = 0.001; OR:1.690;
95%-CI:1.256-2.274), duration of LTX-procedure (p = 0.011;
OR:0.998; 95%-CI:0.997-1.000), living-donor LTX (p < 0.001;
OR:2.826; 95%-CI:1.779-4.489), CIT (p < 0.001; OR:0.999;
95%-CI:0.998-0.999), the use of hepaticojejunostomy
(p < 0.001; OR:2.146; 95%-CI:1.618-2.848), PVT (p = 0.012;
OR:0.439; 95%-CI:0.213-0.905), pediatric LTX (p = 0.005;
OR:1.571; 95%-CI:1.156-2.136), era in which the transplant
was performed (p < 0.001; OR:1.584; 95%-CI:1.360-1.894),
the indications viral hepatitis (yes/no) (p = 0.001; OR:0.410;














































































Figure 1 Distribution of preservation solution in the Hannover (A) and Kiel (B) cohort as well as usage of solutions over the follow-up
time in the Hannover (C) and Kiel cohort (D).
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http://www.biomedcentral.com/1471-230X/14/169OR:0.524; 95%-CI:0.288-0.953) and biliary atresia (yes/no)
(p < 0.001; OR:2.251; 95%-CI:1.489-3.405). Moreover, the
beneficial influence of HTK on the rate of biliary
stenosis could not be confirmed in a multivariate
regression model (p = 0.122), which was risk-adjusted for
the occurrence of HAT (p < 0.001; OR:5.398; 95%-CI:2.865-
10.171) and the era in which the transplant was performed
(p = 0.001; OR:1.486; 95%-CI:1.162-1.899). Analysis of
cases with post-transplant cholangitis (p = 0.353) as
well as not specified biliary complications (p = 0.254)
remained insignificant.Length of hospital and ICU stay
Neither the length of hospital stay (p = 0.113) nor the
length of ICU stay (p = 0.481) after LTX were affected by
the choice of PS.
Pediatric and living donor transplant
22.5% of the Hannover cohort were pediatric patients
(n = 575). HTK was used more often in this subgroup
(n = 302; 52.5%) than UW (n = 273; 47.5%) (p < 0.001; Chi2).
None of the solutions influenced long-term patient







Figure 2 Results of univariate Kaplan Meier analysis of patient (A) and graft (B) survival distributed by the preservation solution in the
Hannover cohort as well as patient (C) and graft (D) survival in the Kiel cohort.
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(p = 0.126). In the pediatric subgroup, the onset of
biliary complications was not influenced by the choice
of PS (p = 0.059).
125 patients (4.9%) received a living-donor related
transplant during follow-up. In 114 cases (91.2%) a
HTK-preserved organ was transplanted; in 11 cases
(8.8%) UW-solution was used (p < 0.001; Chi2). None of
the solutions influenced long-term patient (p = 0.125)
and graft survival (p = 0.085) or three-month mortality
(p = 0.258) and three-month graft survival (p = 0.181). 33
patients (26.4%) developed biliary complications after
living-donor related LTX. All of these transplanted grafts
had been conserved with HTK, thus there is a statistically
significant association between HTK-use and biliary
complications in this sub-cohort (p = 0.036).
Prolonged cold ischemic time
Definition of prolonged CIT is outlined in the Methods
section. 346 (13.5%) patients received an organ that was
exposed to a prolonged CIT. 116 of these (33.5%) donororgans have been preserved with HTK and 230 (66.5%)
using UW (p < 0.001; Chi2). In this sub-cohort, the
choice of PS had no statistically significant influence
on long-term patient (p = 0.989) and graft (p = 0.796)
survival as well as three-month mortality (p = 0.550)
and three-month graft survival (p = 0.724).
Furthermore, there was no statistically significant
difference between the rate of biliary complications in
the two PS cohorts (p = 0.097).
The Kiel cohort
In Kiel, 223 patients (38.4%) received a UW-preserved
organ and 375 patients (61.6%) a HTK-preserved donor
liver (see Figure 1B). Part of this cohort were 80 living
donor related LTX (13.8%) and 87 pediatric recipients
(15%). The mean CIT was 602 minutes (SD: 152 minutes).
A subset analysis equivalent to the Hannover cohort was
performed for the Kiel cohort without significantly differing
results (data not shown). It was thus decided to report the
Hannover cohort’s results, since this cohort appears to be
the larger group of patients.
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p < 0.001; Log Rank) as well as graft (Figure 2D; p = 0.007;
Log Rank) survival were associated with the choice of PS.
However, long-term patient (p = 0.798) and graft survival
(p = 0.454) were not influenced by the PS in multivariate
analysis (adjusted for living donor transplantation, number
of operative revisions, recipient age at transplant and era;
all p < 0.001). Investigation of short-term outcome also
revealed no significant results in risk-adjusted regression
analysis (short-term mortality: p = 0.576; short-term
graft survival: p = 0.396). The PS had no influence on the
occurrence of biliary complications (p = 0.728) or the
necessity of operative revisions (p = 0.256).
An average of 4,869 ml UW solution was used for
donor organ preservation (median 5,000 ml; range
1,500-10,000 ml). HTK preservation needed higher
amounts of averaged 8,303 ml (median 8,000; range
1,000-17,000). Neither the amount of UW nor of
HTK was associated with three-month mortality
(UW: p = 0.518; HTK: p = 0.417) or graft survival
(UW: p = 0.789; HTK: p = 0.053), biliary complications
(UW: p = 0.518; HTK: p = 0.955) as well as long-term
patient (UW: p = 0.395; HTK: p = 0.021, HR:1.000) or graft
survival (UW: p = 0.454; HTK: p = 0.026, HR:1.000).
Economical evaluation
The costs for HTK per liter range between 50 and 56
Euro based on the amount of ordered units in Germany.
There is currently no governmental approval for UW,
thus no UW solution available on the German market.
We therefore retrieved the costs of UW per liter from
the literature, where costs of 181 Dollar per liter (≈136
Euro) are stated for UW on the US market [1]. Based on
this information and taking the mean amount of PS into
account, preservation of an average liver graft with HTK
costs 415 Euro, whereas an average UW-perfused graft
costs 662 Euro. Furthermore, the costs for the said
additives for preparation of UW solution have to be
taken into account.
Discussion
Both HTK and UW are widely used for graft preservation
in solid organ transplantation [4,14,15]. There are several
studies available on the influence of the PS on outcome
defined as survival, onset of complications (especially in
the biliary tract) and rejection rates [4,5,14,15]. The results
of these studies range from equality of the solutions [4] to
favoring one or the other [5,10], thus the evidence-based
choice of preservation solution remained a matter of
controversy. Our local clinical situation is actually
sharpened by the concerning fact that UW has currently
no valid license for organ preservation and is thus not
available in Germany. This has become problematic, since
there are organs donated in other Eurotransplant partnernations, e.g. Belgium, where UW is still approved and
used, leaving German transplant physicians without the
possibility to re-perfuse an organ flown in from these
countries. We recently experienced such an unfortunate
and evitable event. A clinical, evidence-based standard to
support the choice of PS use is thus indispensable.
We therefore performed an analysis with the data of two
liver transplant centers (Hannover and Kiel, Germany),
which are both within the Eurotransplant community and
applied widely established statistical methods rigorously to
compare the preservation solutions’ influence on short- and
long-term patient and graft survival, complications after
LTX as well as the length of hospital and ICU stay.
Competing risks were identified as possible confounders
and systematically taken into account in multivariate
analysis. An advantage of this study is the large number
of included cases (total n = 3134), which represents, at
least to our knowledge, the largest non-registry-based
investigation of this kind available at the moment.
We believe that including both analyses of the
Hannover and Kiel cohorts significantly improves the
grade of information of the manuscript. On the one
hand, the major relevant data, e.g. on patient and graft
survival or the PS applied is given in both datasets and
was investigated to reveal the PS’s impact on outcome
and reduce the possible center bias. On the other hand,
interesting data, such as the amount of perfused PS or
the secondary study endpoints like post-transplant
complications was only available from one of the two
co-operating transplant centers. Nevertheless, this is
relevant information; therefore, the combination of the
results in this manuscript seems warranted.
Short- and long-term patient survival was not influenced
by the choice of PS. Although long-term graft survival
seemed to be increased by HTK-use (see Figure 2A), this
effect could not be confirmed in risk-adjusted analysis.
Furthermore, 3-month graft survival did not differ in the
two PS cohorts. Since no association between the PS and
common complications could be shown, we assume that
HTK and UW are clinically equivalent choices and no PS
can be preferred in terms of influence on the short- or
long-term outcome after LTX. This can be confirmed for
living donor as well as pediatric LTX. The data further
revealed that it does not matter how much solution is
actually used for preservation, as long the amount seems
clinically sufficient (the investigated amounts of PS range
from 1,500-10,000 ml UW and 1,000-17,000 ml HTK).
To answer the question whether one of the solutions is
preferable in situations with extensively prolonged CIT,
this subgroup was defined, identified and subsequently
analyzed. Also in this subset analysis the choice of PS
made no statistically significant difference regarding
short- and long-term patient and graft survival as well
as the onset of post-transplant complications.
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the onset of biliary complications after LTX is still a matter
of controversy [6-10]. This aspect was therefore analyzed in
depth resulting in no statistically significant difference
between UW and HTK in means of onset of either biliary
leakage (p = 0.572), stenosis (p = 0.122), post-transplant
cholangitis (p = 0.353) and not further specified biliary
complications (p = 0.254). The result that there might be
more biliary complications after living-donor LTX is prob-
ably biased by the overall larger number of HTK-perfused
grafts in this subgroup (HTK-use in 91.2%). Another
possible explanation for this observation may be caused by
differing practices in perfusion of the segment IV artery and
the segment IV bile duct with PS. Furthermore, it is known
that partial liver grafts are associated with increased bile
duct leaks from the liver resection surface.
Since our data suggests that there is no clinical difference
between UW and HTK in LTX, economic considerations
can play an important role for the choice of PS. As one
important economical factor we analyzed the PS’s impact
on length of hospital and ICU stay, which was both not
affected by the PS. HTK is clinically easier to handle,
because it is sold in ready-to-use units while UW must be
mixed with additives prior to use, although this might not
be done anymore in some centers without deteriorating
outcome [1]. Furthermore, the quicker perfusion of
the graft with HTK compared to UW can be seen as
cost-benefit advantage (“time is money”). However,
this effect is reduced by the fact that in average twice the
amount of HTK is flushed. The routine use of expensive
medications, including the PS, has been identified as one
driving factor of cost-increase in transplantation [16]. The
costs per liter vary drastically between the two investigated
PS leading to the conclusion that HTK is the solution with
the economically superior profile. A study aiming to find a
cost prediction model for LTX from 2008 [17] nevertheless
reported that the median total cost of LTX significantly
differs regarding two cohorts with either UW or HTK
usage in favor of UW, although this result was not
validated by a multivariate analysis. Also the number
of included patients was smaller (n = 139) than our
study-population. Further investigations of these important
economic aspects are needed to fully understand these
interesting findings.
In conclusion, it is hard to really determine the
economical impact of the PS, especially in the setting
of this study. Due to center volume and individual
negotiations there are different prices even among
centers in the same region or country.
This study is limited due to the fact that non heart-
beating donation is legally prohibited in Germany and
thus no such cases could be included. This aspect might
be partly responsible for the discrepancy between our
results and the UNOS-registry study by Stewart et al.from 2009 [5], in which grafts donated after cardiac
death were included.
It is somehow surprising that the rates of HAT
and PVT are currently increasing as compared to the
previous eras (see Table 2), which might be due to
the improved diagnostic capacities and thus higher
detection rates rather than worsening results. Another
important aspect in this context is the notion that
with the introduction of MELD-based liver allocation
and the “sickest-first-principle” in Germany, patients
accepted for a transplant tend to be sicker nowadays than
in earlier eras [18,19]. This might be also reflected in the
increasing lengths of hospital and ICU stay (see Table 2).
Deteriorating outcome and/or stagnating progress in LTX,
especially for some indications such as PSC, is currently
under hot debate in Germany and the shown data
(Tables 2 and 3) underlines this observation [20], which is
in sharp contrast to improved outcome recently reported
from a large US series [21].
Recently published data on a biochemically improved
HTK solution may provide a promising option for the
future [22]. Liu and colleagues reported that HTK-N solu-
tion, which is modified with N-actylhistidine, amino-acids
and iron chelators, protects liver grafts with microvesicular
steatosis better than common HTK in a rat model [22].
This result is especially interesting given the expanding use
of extended donor criteria in LTX. Celsior solution
might also be able to show some advantages, which was
underlined in a recent prospective multicenter trial from
France [23]. Further studies are needed, preferably with
higher levels of evidence such as prospective multicenter
trials or randomized registry trials to investigate the
preliminary results of our study. In times of chronic-
ally diminishing donation rates in Germany [19], it is
the transplant society’s responsibility to ensure the
best possible preservation of the scarce donor organs.
Thus, further investigations regarding this topic are
warranted.
Conclusions
UW and HTK are clinically equivalent. HTK could have
an economically superior profile. However, it is hard to
really determine the economical impact of the PS, especially
in the setting of this study. The notion that the choice of
preservation solution can have an impact on the onset of
biliary complications after liver transplantation remains a
matter of controversy. All authors read and approved the
final manuscript.Additional file
Additional file 1: STROBE Statement—Checklist of items that
should be included in reports of cohort studies.
Kaltenborn et al. BMC Gastroenterology 2014, 14:169 Page 9 of 9
http://www.biomedcentral.com/1471-230X/14/169Abbreviations
CIT: Cold ischemic time; HAT: Hepatic artery thrombosis; HCC: Hepatocellular
carcinoma; HR: Hazard ratio; HTK: Histidine-Tryptophane-Ketoglutarate
solution; ICU: Intensive care unit; LOS: Length of hospital stay; LTX: Liver
transplantation; OR: Odds ratio; PS: Preservation solution; PSC: Primary
sclerosing cholangitis; PVT: Portal vein thrombosis; SD: Standard deviation;
UW: University of Wisconsin solution; 95%-CI: 95%-confidence interval.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AK, HS and BR participated in the design of the study and performed the
statistical analysis. The data was collected by AK, FL, JK, HS and BR. The
manuscript was drafted by AK, JG, HS and BR and critically revised by AK, JG,
VA, CK, FL, FB, JK, HS and BR. All authors read and approved the final
manuscript.
Authors’ information
Benedikt Reichert and Harald Schrem, both authors share last authorship.
Acknowledgments
The authors would like to thank Catherine Bourg for her support during
preparation of this manuscript. No third-party funding was received for this
study.
Author details
1Department of General, Visceral and Transplant Surgery, Hannover Medical
School, Carl-Neuberg-Str. 1, Hannover 30625, Germany. 2Department of
Trauma and Orthopedic Surgery, Federal Armed Forces Hospital Westerstede,
Westerstede, Germany. 3Department Health Economics and Health Systems
Research of the Institute of Epidemiology, Social Medicine and Health
Systems Research, Hannover Medical School, Hannover, Germany.
4Department of General and Thoracic Surgery, University Hospital
Schleswig-Holstein, Kiel, Germany.
Received: 1 March 2014 Accepted: 12 September 2014
Published: 28 September 2014
References
1. Bellamy CA, Nicely B, Mattice BJ, Teaster R: Comparative analysis of clinical
efficacy and cost between University of Wisconsin solution and
histidine-tryptophan-ketoglutarate. Prog Transplant 2008, 18:166–171.
2. Guarrera JV, Karim NA: Liver preservation: is there anything new yet?
Curr Opin Organ Transplant 2008, 13:148–154.
3. Fridell JA, Agarwal A, Milgrom ML, Goggins WC, Murdock P, Pescovitz MD:
Comparison of histidine-tryptophan-ketoglutarate solution and University
of Wisconsin solution for organ preservation in clinical pancreas
transplantation. Transplantation 2004, 77:1304–1306.
4. Feng L, Zhao N, Yao X, Sun X, Du L, Diao X, Li S, Li Y: Histidine-tryptophan-
ketoglutarate solution vs. University of Wisconsin solution for liver
transplantation: a systematic review. Liver Transpl 2007, 13:1125–1136.
5. Stewart ZA, Cameron AM, Singer AL, Montgomery RA, Segev DL:
Histidine-Tryptophan-Ketoglutarate (HTK) is associated with reduced
graft survival in deceased donor livers, especially those donated after
cardiac death. Am J Transplant 2009, 9:286–293.
6. Rayya F, Harms J, Martin AP, Bartels M, Hauss J, Fangmann J: Comparison of
histidine-tryptophan-ketoglutarate solution and University of Wisconsin
solution in adult liver transplantation. Transplant Proc 2008, 40:891–894.
7. Moench C, Otto G: Ischemic type biliary lesions in histidine-tryptophan-
ketoglutarate (HTK) preserved liver grafts. Int J Artif Organs 2006, 29:329–334.
8. Meine MH, Zanotelli ML, Neumann J, Kiss G, De Jesus Grezzana T, Leipnitz L,
Schlindwein ES, Fleck A Jr, Gleisner AL, de Mello Brandão A, Marroni CA,
Cantisani GP: Randomized clinical assay for hepatic grafts preservation
with University of Wisconsin or histidine-tryptophan-ketoglutarate solutions
in liver transplantation. Transplant Proc 2006, 38:1872–1875.
9. Welling TH, Heidt DG, Englesbe MJ, Magee JC, Sung RS, Campbell DA,
Punch JD, Pelletier SJ: Biliary complications following liver transplantation
in the model for end-stage liver disease era: effect of donor, recipient,
and technical factors. Liver Transpl 2008, 14:73–80.10. Mangus RS, Tector AJ, Agarwal A, Vianna R, Murdock P, Fridell JA:
Comparison of histidine-tryptophan-ketoglutarate solution (HTK) and
University of Wisconsin solution (UW) in adult liver transplantation.
Liver Transpl 2006, 12:226–230.
11. Chan SC, Liu CL, Lo CM, Fan ST: Applicability of histidine-tryptophan-
ketoglutarate solution in right lobe adult-to-adult live donor liver
transplantation. Liver Transp 2004, 10:1415–1421.
12. Canelo R, Hakim NS, Ringe B: Experience with hystidine tryptophan
ketoglutarate versus University Wisconsin preservation solutions in
transplantation. Int Surg 2003, 88:145–151.
13. Erhard J, Lange R, Scherer R, Kox WJ, Bretschneider HJ, Gebhard MM,
Eigler FW: Comparison of histidine-tryptophan-ketoglutarate (HTK)
solution versus University of Wisconsin (UW) solution for organ preservation
in human liver transplantation. A prospective randomized study.
Transplant Int 1994, 7:177–181.
14. Jamieson RW, Friend PJ: Organ reperfusion and preservation. Front Biosci
2008, 13:221–235.
15. Wilson CH, Brook NR, Talbot D: Preservation solutions for solid organ
transplantation. Mini Rev Med Chem 2006, 6:1081–1090.
16. Portela MP, Neri ED, Fonteles MM, Garcia JH, Fernandes ME: The cost of
liver transplantation at a university hospital of Brazil. Rev Assoc Med Bras
2010, 56:322–326.
17. Earl TM, Cooil B, Rubin JE, Chari RS: Cost prediction in liver transplantation
using pretransplant donor and recipient characteristics. Transplantation 2008,
86:238–244.
18. Weismüller TJ, Fikatas P, Schmidt J, Barreiros AP, Otto G, Beckebaum S, Paul A,
Scherer MN, Schmidt HH, Schlitt HJ, Neuhaus P, Klempnauer J, Pratschke J,
Manns MP, Strassburg CP: Multicentric evaluation of model for end-stage
liver disease-based allocation and survival after liver transplantation in
Germany–limitations of the ‘sickest first’-concept. Transpl Int 2011, 24:91–99.
19. Schrem H, Kaltenborn A: Germany: Avoid more organ transplant scandals.
Nature 2013, 498:37.
20. Klose J, Klose MA, Metz C, Lehner F, Manns MP, Klempnauer J, Hoppe N,
Schrem H, Kaltenborn A: Outcome stagnation of liver transplantation for
primary sclerosing cholangitis in the Model for End-Stage Liver Disease
era. Langenbecks Arch Surg 2014, [Epub ahead of print].
21. Agopian VG, Petrowsky H, Kaldas FM, Zarrinpar A, Farmer DG, Yersiz H, Holt C,
Harlander-Locke M, Hong JC, Rana AR, Venick R, McDiarmid SV, Goldstein
LI, Durazo F, Saab S, Han S, Xia V, Hiatt JR, Busuttil RW: The evolution of liver
transplantation during 3 decades: analysis of 5347 consecutive liver
transplants at a single center. Ann Surg 2013, 258:409–421.
22. Liu Q, Bruns H, Schultze D, Xue Y, Zorn M, Flechtenmacher C, Straub BK,
Rauen U, Schemmer P: HTK-N, a modified HTK solution, decreases
preservation injury in a model of microsteatotic rat liver transplantation.
Langenbecks Arch Surg 2012, 397:1323–1331.
23. Boudjema K, Grandadam S, Compagnon P, Salamé E, Wolf P, Ducerf C,
Le Treut P, Soubrane O, Cherqui D, Mouchel C, Renault A, Bellissant E:
Efficacy and safety of Celsior preservation fluid in liver transplantation:
one-year follow up of a prospective, multicenter, non-randomized study.
Clin Transplant 2012, 26:199–207.
doi:10.1186/1471-230X-14-169
Cite this article as: Kaltenborn et al.: Comparable outcome of liver
transplantation with Histidine-Tryptophan-Ketoglutarate vs. University
of Wisconsin preservation solution: a retrospective observational
double-center trial. BMC Gastroenterology 2014 14:169.
